Revenue
2022
2023
2024
2025
Milestone Pharmaceuticals Inc. (MIST)
Price$1.20Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $0 | $1.0M | $5.0M | — | — | — | — |
| Research & development | $18.1M | $14.4M | $31.1M | $39.8M | $38.7M | $34.5M | $42.0M | $16.8M |
| Operating expenses | $63.7M | $42.1M | $62.1M | $64.6M | — | — | — | — |
| Operating income | −$62.1M | −$42.1M | −$61.1M | −$59.6M | −$43.1M | −$50.7M | −$57.9M | −$23.8M |
| Operating margin | −4,019.40% | — | −6,109.80% | −1,192.84% | — | — | — | — |
| EBITDA | −$62.0M | −$42.0M | −$61.0M | −$59.6M | −$43.0M | −$50.6M | −$57.8M | −$23.8M |
| EBITDA margin | −4,012.03% | — | −6,100.60% | −1,191.06% | — | — | — | — |
| Net income | −$63.1M | −$41.5M | −$59.7M | −$58.4M | −$42.9M | −$50.0M | −$55.2M | −$23.2M |
| Net profit margin | −4,078.78% | — | −5,968.50% | −1,167.76% | — | — | — | — |
| Basic EPSper basic share | -$0.75 | -$0.67 | -$1.39 | -$1.38 | -$1.02 | -$1.70 | -$3.50 | $72.63 |
| Diluted EPSper diluted share | -$0.75 | -$0.67 | -$1.39 | -$1.38 | -$1.02 | -$1.70 | -$3.50 | $72.63 |
Owners
Reported shareholders
7.28%of listed shares
Pavaki Capital Management LLC9.07M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Pavaki Capital Management LLC | 7.28%9.07M shares |
RTW INVESTMENTS, LP | 6.29%7.83M shares |
Propel Bio Management, LLC | 5.97%7.43M shares |
Point72 Asset Management, L.P. | 4.35%5.41M shares |
Simplify Asset Management Inc. | 2.69%3.35M shares |
MILLENNIUM MANAGEMENT LLC | 2.52%3.14M shares |
Kalehua Capital Management LLC | 2.04%2.54M shares |
TWO SIGMA INVESTMENTS, LP | 1.64%2.04M shares |
MARSHALL WACE, LLP | 1.44%1.8M shares |
Lion Point Capital, LP | 0.66%820K shares |
TORONTO DOMINION BANK | 0.60%750K shares |
AMERIPRISE FINANCIAL INC | 0.54%666.67K shares |
Boxer Capital Management, LLC | 0.54%666.67K shares |
MORGAN STANLEY | 0.51%635.21K shares |
UBS Group AG | 0.37%465.4K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 0.37%462.67K shares |
Oliveto Joseph | ≈0.36%446.24K shares |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.29%359.9K shares |
Aptus Capital Advisors, LLC | 0.27%339.45K shares |
GUARDIAN WEALTH ADVISORS, LLC / NC | 0.27%339.45K shares |
Percentages use 124.5M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 16, 2026Form 4 · 10b5-1 | Oliveto JosephPresident and CEO | SellCommon Shares | 36.5K | $2.26 | $82.5K | 446.2K |
| Jan 26, 2026Form 4 | Nelson Jeffrey EdwardChief Operating Officer | SellCommon Shares | 12.2K | $1.93 | $23.6K | 49.8K |
| Jan 26, 2026Form 4 | Bharucha DavidChief Medical Officer | SellCommon Shares | 12.2K | $1.93 | $23.6K | 113.2K |
| Jan 26, 2026Form 4 | Hasija AmitCFO & EVP of Corp. Development | SellCommon Shares | 12.2K | $1.93 | $23.6K | 99.8K |
| Jan 26, 2026Form 4 | Muller LorenzChief Commercial Officer | SellCommon Shares | 11.2K | $1.93 | $21.6K | 205.4K |